Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis

Cell Death and Differentiation

Volumn 13, Issue 1, 2006, Pages 129-140

  Zhang, Y ^a,b   Adachi, M ^a,b   Kawamura, R ^a,b   Imai, K ^b  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acetylation; Apoptosis; Bmf; Histone deacetylase inhibitor; Transcription

Indexed keywords

BH3 PROTEIN; BMF PROTEIN; DNA FRAGMENT; FR 901228; GENE PRODUCT; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; M CARBOXYNNAMIC ACID BIS HYDROXAMIDE; PROTEIN BID; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BMF PROTEIN, HUMAN; CARBOXYCINNAMIC ACID BISHYDROXAMIDE; CINNAMIC ACID DERIVATIVE; CISPLATIN; DEPSIPEPTIDE; ENZYME INHIBITOR; HISTONE; HISTONE DEACETYLASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA;

ACETYLATION; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG MECHANISM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UPREGULATION; CELL SURVIVAL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; LEUKEMIA CELL LINE; METABOLISM; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; RNA INTERFERENCE; TRANSACTIVATION; TUMOR CELL LINE;

ACETYLATION; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; CELL SURVIVAL; CINNAMATES; CISPLATIN; DEPSIPEPTIDES; ENZYME INHIBITORS; GENES, REPORTER; HISTONE DEACETYLASES; HISTONES; HUMANS; JURKAT CELLS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANS-ACTIVATION (GENETICS); TRANSFECTION;

EID: 31544466465     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401686     Document Type: Article

References (38)

1. Kouzarides T (2000) Acetylation: A regulatory modification to rival phosphorylation? EMBO J. 19: 1176-1179
2. Yoshida M and Horinouchi S (1999) Trichostatin and leptomycin. Inhibition of histone deacetylation and signal-dependent nuclear export. Ann. NY. Acad. Sci. 886: 23-36
3. Marks PA, Richon VM and Rifkind RA (2000) Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92: 1210-1216
4. Nervi C, Borello U, Fazi F, Buffa V, Pelicci PG and Cossu G (2001) Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. Cancer Res. 61: 1247-1249
5. Goldsmith ME, Kitazono M, Fok P, Aikou T, Bates S and Fojo T (2003) The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells. Clin. Cancer Res. 9: 5394-5401
6. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA, Waterhouse NJ, Trapani JA and Johnstone RW (2003) Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 63: 4460-4471
7. Vigushin DM and Coombes RC (2002) Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13: 1-13
8. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M and Horinouchi S (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62: 4916-4921
9. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, BenderJ, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP and Bates SE (2002) Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8: 718-728
10. Piekarz RL, Robey RW, Zhan Z, Kayastha G, Sayah A, Abdeldaim AH, Torrico S and Bates SE (2004) T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: Impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103: 4636-4643
11. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA and Marks PA (1996) Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. USA 93: 5705-5708
12. Glick RD, Swendeman SL, Coffey DC, Rifkind RA, Marks PA, Richon VM and La Quaglia MP (1999) Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res. 59: 4392-4399
13. Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, Rifkind RA, Marks PA, Richon VM and La Quaglia MP (2001) The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res. 61: 3591-3594
14. Richon VM, Sandhoff TW, Rifkind RA and Marks PA (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97: 10014-10019
15. Han JW, Ahn SH, Park SH, Wang SY, Bae GU, Seo DW, Kwon HK, Hong S, Lee HY, Lee YW and Lee HW (2000) Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res. 60: 6068-6074
16. Ju R and Muller MT (2003) Histone deacetylase inhibitors activate p21(WAF1) expression via ATM. Cancer Res. 63: 2891-2897
17. Kim JH, Choi YK, Kwon HJ, Yang HK, Choi JH and Kim DY (2004) Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1. J. Gastroenterol. Hepatol. 19: 218-224
18. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M and Sakai T (2004) Histone deacetylase inhibitors upregulate death receptor 5/ TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23: 6261-6271
19. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA and Schrump DS (2002) Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. 94: 504-513
20. Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P and Bhalla K (2003) Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 63: 5126-5135
21. Watanabe K, Okamoto K and Yonehara S (2005) Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ. 12: 10-18
22. Cohen HY, Lavu S, Bitterman KJ, Hekking B, Imahiyerobo TA, Miller C, Frye R, Ploegh H, Kessler BM and Sinclair DA (2004) Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol. Cell 13: 627-638
23. Zhang Y, Adachi M, Zhao X, Kawamura R and Imai K (2004) Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl- methoxy-carbonyl) amino- methyl] benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int. J. Cancer 110: 301-308
24. Lei K and Davis RJ (2003) JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc. Natl. Acad. Sci. USA 100: 2432-2457
25. Koyama Y, Adachi M, Sekiya M, Takekawa M and Imai K (2002) Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. Blood 96: 1490-1495
26. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG and Davidsen SK (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2: 151-163
27. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA and Anderson KC (2003) Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101: 4055-4062
28. Moore PS, Barbi S, Donadelli M, Costanzo C, Bassi C, Palmieri M and Scarpa A (2004) Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochem. Biophys. Acta 1693: 167-176
29. Khan SB, Maududi T, Barton K, Ayers J and Alkan S (2004) Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br. J. Haematol. 125: 156-161
30. Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME, Shen T, Murphy T, Wickham J, Kanakry C, Lucas DM, Reed JC, Grever MR and Byrd JC (2003) Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 102: 652-658
31. Braganca J, Eloranta JJ, Bamforth SD, Ibbitt JC, Hurst HC and Bhattacharya S (2003) Physical and functional interactions among AP-2 transcription factors, p300/CREB-binding protein, and CITED2. J. Biol. Chem. 278: 16021-16029
32. Chrivia JC, Kwok RP, Lamb N, Hagiwara M, Montminy MR and Goodman RH (1993) Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365: 855-859
33. Owen GI, Richer JK, Tung L, Takimoto G and Horwitz KB (1998) Progesterone regulates transcription of the p21WAF1 cyclindependent kinase inhibitor gene through Sp1 and CBP/p300. J. Biol. Chem. 273: 10696-10701
34. Itoh T, Itoh A and Pleasure D (2003) Bcl-2-related protein family gene expression during oligodendroglial differentiation. J. Neurochem. 85: 1500-1512
35. Morales AA, Olsson A, Celsing F, Osterborg A, Jondal M and Osorio LM. (2004) Expression and transcriptional regulation of functionally distinct Bmf isoforms in B-chronic lymphocytic leukemia cells. Leukemia 18: 41-47
36. Puthalakath H, Villunger A, O'Reilly LA, Beaumont JG, Coultas L, Cheney RE, Huang DC and Strasser A (2001) Bmf: A proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 293: 1829-1832
37. Takaoka A, Adachi M, Okuda H, Sato S, Yawata A, Hinoda Y, Takayama S, Reed JC and Imai K (1997) Anti-cell death activity promotes pulmonary metastasis of melanoma cells. Oncogene 14: 2971-2977
38. Itoh M, Adachi M, Yasui H, Takekawa M, Tanaka H and Imai K (2002) Nuclear export of glucocorticoid receptor is enhanced by c-Jun N-terminal kinase-mediated phosphorylation. Mol Endocrinol. 16: 2382-2392